Glycogen Synthase Kinase 3 (Gsk-3) and Its Inhibitors

Drug Discovery and Development
1. Auflage 2006
ISBN: 978-0-471-77001-5
Verlag: Wiley

Buch, Englisch, 392 Seiten, Format (B × H): 162 mm x 242 mm, Gewicht: 672 g

Many researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It’s a great reference for researchers in drug design and development.

Autoren/Hrsg.

Martinez, Ana

Castro, Ana

Medina, Miguel

Wang, Binghe

Weitere Mitwirkende

Wang, Binghe

Fachgebiete

• Naturwissenschaften Chemie Organische Chemie Supramolekularchemie
• Naturwissenschaften Chemie Organische Chemie Biochemie

Inhaltsverzeichnis

Foreword: The Origins of GSK-3. Preface. Acknowledgments. Contributors. Abbreviations.  PART I: CELLULAR FUNCTIONS OF GSK-3. 1. Glycogen Synthase Kinase-3 - an Introductory Synopsis . 2. Glycogen-Synthase-Kinase-ß (GSK-3ß) a Key Signaling Enzyme: A Developmental Neurobiological Perspective. 3. Role of GSK3/Shaggy in neuronal cell biology. 4. The Crystal Structures of Glycogen Synthase Kinase 3. 5. Kinase-Kinase and Site-Site Interactions in the Phosphorylation of Tau by GSK-3. PART II: GSK3 AS A THERAPEUTIC TARGET IN HUMAN PATHOLOGY. 6. GSK-3, a Key Player in Alzheimer’s Disease. 7. Glycogen Synthase Kinase-3: A Target for Novel Mood Disorder Treatments. 8. GSK3 and Stem Cells. 9. Glycogen Synthase Kinase-3: role in Neurodegeneration and Neuroprotection. 10. Protein Kinase Inhibitors. Assay Development. 11. Animal Models with Modified Expression of GSK-3 for the Study of Its Physiology and of Its Implications in Human Pathologies. PART III: GSK-3 INHIBITORS: DEVELOPMENT AND THERAPEUTIC POTENTIAL. 12. Lithium, the Seminal GSK3 Inhibitor. 13. Inhibition of GSK3 as Therapeutic Strategy in Disease: Efficacy of AR-A014418. 14. TDZD’s: Selective And ATP Non Competitive Glycogen Synthase Kinase-3 Inhibitors. 15. 3-Amino Pyrazoles as Potent and Selective Glycogen Synthase (GSK-3) Inhibitors. 16. Marine compounds as a new source for Glycogen Synthase Kinase-3 Inhibitors. Index.

Über Autor(innen)

ANA MARTINEZ is the Research and Development Director for NeuroPharma. She has been and still is an active researcher in the design and synthesis of GSK-3 inhibitors.
ANA CASTRO is the Medicinal Chemistry Director of NeuroPharma. She was formerly a tenured scientist at the Medicinal Chemistry Institute.

MIGUEL MEDINA is the Drug Discovery Director at NeuroPharma. He was formerly an instructor at the Brigham and Women's Hospital and the Harvard Medical School.